Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

Diabetes, Obesity and Metabolism

Volumn 16, Issue 10, 2014, Pages 1016-1027

  Yale, J F ^a   Bakris, G ^b   Cariou, B ^c   Nieto, J ^d   David Neto, E ^e   Yue, D ^f   Wajs, E ^g   Figueroa, K ^h   Jiang, J ^h   Law, G ^h   Usiskin, K ^h   Meininger, G ^h  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Hospital General Universitario   (Spain)

^e HOSPITAL SÍRIO LIBANÊS   (Brazil)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diabetic nephropathy; Randomized trial; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; CANAGLIFLOZIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; AGED; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC PYELONEPHRITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRACTURE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OSMOTIC DIURESIS; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY TRACT INFECTION; UROLITHIASIS; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME;

EID: 84912527805     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12348     Document Type: Article

References (31)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009; 31: 2608-2617.
3. Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 2007; 25: 90-97.
4. Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol 2013; 9: 147-153.
5. Charbonnel B, Cariou B. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab 2011; 13: 99-117.
6. INVOKANA™(canagliflozin) tablets, for oral use [package insert]. Titusville: Janssen Pharmaceuticals, 2013.
7. Invokana 100 mg film-coated tablets. Summary of Product Characteristics. 2013. Available from URL: http://www.medicines.org.uk/emc/medicine/28400/SPC/Invokana+100+mg+film-coated+tablets/. Accessed 4 February 2014.
8. Stenlöf K, Cefalu WT, Kim K-A et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
9. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
10. Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515.
11. Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
12. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84.
13. Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592.
14. Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
15. Forst T, Guthrie R, Goldenberg R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477.
16. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672.
17. Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555.
18. National Kidney Foundation, Kidney Disease Outcomes Quality Initiative. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. 2002. Available from URL: http://www. kidney.org/professionals/kdoqi/pdf/ckd_evaluation_classification_ stratification.pdf. Accessed 10 February 2014.
19. Stenlöf K, Cefalu WT, Kim KA et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175.
20. Weidmann P, de Courten M, Ferrari P. Effect of diuretics on the plasma lipid profile. Eur Heart J 1992; 13(Suppl. G): 61-67.
21. Neal B, Perkovic V, de Zeeuw D et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013; 166: 217-223.
22. Nyirjesy P, Sobel JD, Fung A et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109-1119.
23. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized Phase III studies of canagliflozin, a sodium glucose cotransporter 2 inhibitor. Postgrad Med 2014; 126: 7-17.
24. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
25. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
26. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
27. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
28. Wilding JP, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
29. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
30. The National Kidney Disease Education Program (NKDEP). Urine Albuminto- Creatinine Ratio (UACR) in Evaluating Patients with Diabetes for Kidney Disease, 2010.
31. Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010; 8: 604-611.